Nebulised Surfactant in Preterm Infants with or at Risk of Respiratory Distress Syndrome

Overview

Journal Cochrane Database Syst Rev

Publisher Wiley

Specialties General Medicine
Health Services

Date 2012 Oct 19

PMID 23076945

Citations 18

Authors

Mohamed E Abdel-Latif

David A Osborn

Affiliations

Soon will be listed here.

Abstract

Background: Nebulised surfactant has the potential to deliver surfactant to the infant lung with the goal of avoiding endotracheal intubation and ventilation, ventilator-induced lung injury and bronchopulmonary dysplasia (BPD).

Objectives: To determine the effect of nebulised surfactant administration either as prophylaxis or treatment compared to placebo, no treatment or intratracheal surfactant administration on morbidity and mortality in preterm infants with, or at risk of, respiratory distress syndrome (RDS).

Search Methods: Searches were performed of CENTRAL (The Cochrane Library, January 2012), MEDLINE and PREMEDLINE (1950 to January 2012), EMBASE (1980 to January 2012) and CINAHL (1982 to January 2012), as well as proceedings of scientific meetings, clinical trial registries, Google Scholar and reference lists of identified studies. Expert informants and surfactant manufacturers were contacted.

Selection Criteria: Randomised, cluster-randomised or quasi-randomised controlled trials of nebulised surfactant administration compared to placebo, no treatment, or other routes of administration (laryngeal, pharyngeal instillation of surfactant before the first breath, thin endotracheal catheter surfactant administration or intratracheal surfactant instillation) on morbidity and mortality in preterm infants at risk of RDS. We considered published, unpublished and ongoing trials.

Data Collection And Analysis: Two review authors independently assessed studies for eligibility and quality, and extracted data.

Main Results: No studies of prophylactic or early nebulised surfactant administration were found. A single small study of late rescue nebulised surfactant was included. The study is of moderate risk of bias. The study enrolled 32 preterm infants born < 36 weeks' gestation with RDS on nasal continuous positive airway pressure (nCPAP). The study reported no significant difference between nebulised surfactant administration compared to no treatment groups in chronic lung disease (risk ratio (RR) 5.00; 95% confidence interval (CI) 0.26 to 96.59) or other outcomes (oxygenation 1 to 12 hours after randomisation, need for mechanical ventilation, days of mechanical ventilation or continuous positive airways pressure (CPAP) or days of supplemental oxygen). No side effects of the nebulised surfactant therapy or aerosol inhalation were reported.

Authors' Conclusions: There are insufficient data to support or refute the use of nebulised surfactant in clinical practice. Adequately powered trials are required to determine the effect of nebulised surfactant administration for prevention or early treatment of RDS in preterm infants. Nebulised surfactant administration should be limited to clinical trials.

Citing Articles

Non-invasive high-frequency ventilation in newborn infants with respiratory distress.

Abdel-Latif M, Tan O, Fiander M, Osborn D Cochrane Database Syst Rev. 2024; 5:CD012712.

PMID: 38695628 PMC: 11064768. DOI: 10.1002/14651858.CD012712.pub2.

Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants with or at risk of respiratory distress syndrome.

Abdel-Latif M, Walker E, Osborn D Cochrane Database Syst Rev. 2024; 1():CD008309.

PMID: 38270182 PMC: 10809312. DOI: 10.1002/14651858.CD008309.pub3.

Prophylactic Oropharyngeal Surfactant for Preterm Newborns at Birth: A Randomized Clinical Trial.

Murphy M, Miletin J, Klingenberg C, Guthe H, Rigo V, Plavka R JAMA Pediatr. 2023; 178(2):117-124.

PMID: 38079168 PMC: 10714282. DOI: 10.1001/jamapediatrics.2023.5082.

Surfactant therapy guided by tests for lung maturity in preterm infants at risk of respiratory distress syndrome.

Sibrecht G, Kearl C, Borys F, Morariu M, Bruschettini M, Soll R Cochrane Database Syst Rev. 2023; 10:CD013158.

PMID: 37882216 PMC: 10600963. DOI: 10.1002/14651858.CD013158.pub2.

Target product profile: aerosolized surfactant for neonatal respiratory distress.

Rao S, Edmond K, Bahl R Bull World Health Organ. 2023; 101(5):341-345.

PMID: 37131945 PMC: 10140689. DOI: 10.2471/BLT.23.289727.

References

Kribs A, Pillekamp F, Hunseler C, Vierzig A, Roth B . Early administration of surfactant in spontaneous breathing with nCPAP: feasibility and outcome in extremely premature infants (postmenstrual age </=27 weeks). Paediatr Anaesth. 2007; 17(4):364-9. DOI: 10.1111/j.1460-9592.2006.02126.x. View

Davis P, Lemyre B, De Paoli A . Nasal intermittent positive pressure ventilation (NIPPV) versus nasal continuous positive airway pressure (NCPAP) for preterm neonates after extubation. Cochrane Database Syst Rev. 2001; (3):CD003212. DOI: 10.1002/14651858.CD003212. View

Finer N, Carlo W, Walsh M, Rich W, Gantz M, Laptook A . Early CPAP versus surfactant in extremely preterm infants. N Engl J Med. 2010; 362(21):1970-9. PMC: 3071534. DOI: 10.1056/NEJMoa0911783. View

Soll R, Ozek E . Prophylactic protein free synthetic surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2010; (1):CD001079. PMC: 7059181. DOI: 10.1002/14651858.CD001079.pub2. View

Jorch G, HARTL H, Roth B, Kribs A, Gortner L, Schaible T . Surfactant aerosol treatment of respiratory distress syndrome in spontaneously breathing premature infants. Pediatr Pulmonol. 1997; 24(3):222-4. DOI: 10.1002/(sici)1099-0496(199709)24:3<222::aid-ppul9>3.0.co;2-o. View

Bell M, TERNBERG J, Feigin R, Keating J, Marshall R, Barton L . Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg. 1978; 187(1):1-7. PMC: 1396409. DOI: 10.1097/00000658-197801000-00001. View

Bohlin K, Gudmundsdottir T, Katz-Salamon M, Jonsson B, Blennow M . Implementation of surfactant treatment during continuous positive airway pressure. J Perinatol. 2007; 27(7):422-7. DOI: 10.1038/sj.jp.7211754. View

Majnemer A, Riley P, Shevell M, Birnbaum R, Greenstone H, Coates A . Severe bronchopulmonary dysplasia increases risk for later neurological and motor sequelae in preterm survivors. Dev Med Child Neurol. 2000; 42(1):53-60. DOI: 10.1017/s001216220000013x. View

Pfister R, Soll R, Wiswell T . Protein-containing synthetic surfactant versus protein-free synthetic surfactant for the prevention and treatment of respiratory distress syndrome. Cochrane Database Syst Rev. 2009; (4):CD006180. DOI: 10.1002/14651858.CD006180.pub2. View

10.

Hughes C, OGorman L, Shyr Y, Schork M, Bozynski M, McCormick M . Cognitive performance at school age of very low birth weight infants with bronchopulmonary dysplasia. J Dev Behav Pediatr. 1999; 20(1):1-8. DOI: 10.1097/00004703-199902000-00001. View

11.

Dunn M, Kaempf J, de Klerk A, de Klerk R, Reilly M, Howard D . Randomized trial comparing 3 approaches to the initial respiratory management of preterm neonates. Pediatrics. 2011; 128(5):e1069-76. DOI: 10.1542/peds.2010-3848. View

12.

Yost C, Soll R . Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database Syst Rev. 2000; (2):CD001456. DOI: 10.1002/14651858.CD001456. View

13.

Marshall T, Deeder R, Pai S, Berkowitz G, Austin T . Physiologic changes associated with endotracheal intubation in preterm infants. Crit Care Med. 1984; 12(6):501-3. DOI: 10.1097/00003246-198406000-00006. View

14.

Kugelman A, Feferkorn I, Riskin A, Chistyakov I, Kaufman B, Bader D . Nasal intermittent mandatory ventilation versus nasal continuous positive airway pressure for respiratory distress syndrome: a randomized, controlled, prospective study. J Pediatr. 2007; 150(5):521-6, 526.e1. DOI: 10.1016/j.jpeds.2007.01.032. View

15.

Shennan A, Dunn M, Ohlsson A, Lennox K, Hoskins E . Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics. 1988; 82(4):527-32. View

16.

Mazela J, Merritt T, Finer N . Aerosolized surfactants. Curr Opin Pediatr. 2007; 19(2):155-62. DOI: 10.1097/MOP.0b013e32807fb013. View

17.

Chye J, Gray P . Rehospitalization and growth of infants with bronchopulmonary dysplasia: a matched control study. J Paediatr Child Health. 1995; 31(2):105-11. DOI: 10.1111/j.1440-1754.1995.tb00756.x. View

18.

Papile L, BURSTEIN J, Burstein R, KOFFLER H . Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr. 1978; 92(4):529-34. DOI: 10.1016/s0022-3476(78)80282-0. View

19.

Arzhavitina A, Steckel H . Surface active drugs significantly alter the drug output rate from medical nebulizers. Int J Pharm. 2009; 384(1-2):128-36. DOI: 10.1016/j.ijpharm.2009.10.012. View

20.

Aly H . Nasal prongs continuous positive airway pressure: a simple yet powerful tool. Pediatrics. 2001; 108(3):759-61. DOI: 10.1542/peds.108.3.759. View